These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 20375802

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
    Tang CH, Cheng WF, Jiang JH, You SL, Huang LW, Hsieh JY, Mukherjee P, Van Kriekinge G, Lee C.
    Asian Pac J Cancer Prev; 2019 May 25; 20(5):1377-1387. PubMed ID: 31127896
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of human papillomavirus vaccination and screening in Spain.
    Diaz M, de Sanjose S, Ortendahl J, O'Shea M, Goldie SJ, Bosch FX, Kim JJ.
    Eur J Cancer; 2010 Nov 25; 46(16):2973-85. PubMed ID: 20638840
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cost-Utility of a Two-Dose Human Papillomavirus Vaccination Programme Added to Cervical Cancer Screening Compared with Cervical Cancer Screening Alone in Korea.
    Lee H, Hur S, Jang H, Lee IH, Sohn WY, Van Kriekinge G, Kim BG.
    Asian Pac J Cancer Prev; 2019 Feb 26; 20(2):425-435. PubMed ID: 30803204
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in Malaysia.
    Ezat WP, Aljunid S.
    Asian Pac J Cancer Prev; 2010 Feb 26; 11(1):79-90. PubMed ID: 20593935
    [Abstract] [Full Text] [Related]

  • 9. Comparative Cost-Effectiveness Analysis of Two Different Two-Dose Human Papillomavirus Vaccines in Malaysia.
    Van Kriekinge G, Sohn WY, Aljunid SM, Soon R, Yong CM, Chen J, Lee IH.
    Asian Pac J Cancer Prev; 2018 Apr 25; 19(4):933-940. PubMed ID: 29693347
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females.
    Anonychuk AM, Bauch CT, Merid MF, Van Kriekinge G, Demarteau N.
    BMC Public Health; 2009 Oct 31; 9():401. PubMed ID: 19878578
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.
    Health Technol Assess; 2014 Apr 31; 18(23):1-196. PubMed ID: 24762804
    [Abstract] [Full Text] [Related]

  • 17. Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program.
    Östensson E, Hellström AC, Hellman K, Gustavsson I, Gyllensten U, Wilander E, Zethraeus N, Andersson S.
    Acta Obstet Gynecol Scand; 2013 Jul 31; 92(7):830-40. PubMed ID: 23530870
    [Abstract] [Full Text] [Related]

  • 18. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
    Dasbach EJ, Nagy L, Brandtmüller A, Elbasha EH.
    J Med Econ; 2010 Mar 31; 13(1):110-8. PubMed ID: 20085477
    [Abstract] [Full Text] [Related]

  • 19. Present and future of cervical cancer prevention in Spain: a cost-effectiveness analysis.
    Georgalis L, de Sanjosé S, Esnaola M, Bosch FX, Diaz M.
    Eur J Cancer Prev; 2016 Sep 31; 25(5):430-9. PubMed ID: 26375246
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.